Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Velmetia er større end risiciene ved behandling af type 2 - diabetes mellitus.
The Committee for Medicinal Products for Human Use (CHMP) decided that Velmetia’ s benefits are greater than its risks for the treatment of patients with type 2 diabetes mellitus.